Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 16/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833968 | 0.79 | KMT2A (0.65) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17834250 | 0.79 | MYC (0.82) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821352 | 0.78 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821351 | 0.78 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821346 | 0.78 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821347 | 0.78 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821389 | 0.76 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821391 | 0.76 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821393 | 0.75 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 | |
| SCHEMBL17821395 | 0.75 | MYC (1.00) | MYCMAPTALDH1A1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| WO-2016094688-A1 | FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | MYC 1/4885MAPT 2226/4885ALDH1A1 2650/4885 |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | MYC 1/4885MAPT 2226/4885ALDH1A1 2650/4885 |
| US-10017520-B2 | Myc modulators and uses thereof | MYC, MYCBP, MYCBP2 | MYC 1/4885MAPT 2226/4885ALDH1A1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.